Effect of interferon-alpha on experimental septal fibrosis of the liver - study with a new model

AUTOR(ES)

Souza, Marcia Maria de, Paraná, Raymundo, Trepo, Christian, Barbosa Jr, Aryon A, Oliveira, Irismar, Andrade, Zilton A

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

2001-04

RESUMO

Interferon-alpha is used in antiviral therapy in humans, mainly for viral hepatitis B and C. An anti-fibrotic effect of interferon has been postulated even in the absence of anti-viral response, which suggests that interferon directly inhibits fibrogenesis. Rats infected with the helminth Capillaria hepatica regularly develop diffuse septal fibrosis of the liver, which terminates in cirrhosis 40 days after inoculation. The aim of this study was to test the anti-fibrotic effect of interferon in this experimental model. Evaluation of fibrosis was made by three separate methods: semi-quantitative histology, computerized morphometry and hydroxyproline measurements. Treatment with interferon-alpha proved to inhibit the development of fibrosis in this model, especially when doses of 500,000 and 800,000 IU were used for 60 days. Besides confirming the anti-fibrotic potential of interferon-alpha on a non-viral new experimental model of hepatic fibrosis, a clear-cut dose-dependent effect was observed.

Documentos Relacionados

• Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C
• Low dose interferon-alpha is safe in patients with myasthenia gravis.
• Absence of immunoreactive interferon-alpha in CSF from patients with multiple sclerosis.
• Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.
• Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis